HC Wainwright Maintains Genmab Buy, Raises Price Target to $70
HC Wainwright maintained its Buy rating on Genmab and raised its price target to $70 from $50.
HC Wainwright maintained its Buy rating on Genmab and raised its price target to $70 from $50.